Degarelix Dosing Regimen to Prevent Testosterone Spike in Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GnRH agonist and antagonist therapies for prostate cancer treatment are associated with adverse side effects such as testosterone spikes and undesirable side effects like cardiac disorders, urinary tract infections, and increased risk of non-prostate cancer-related mortality, despite their promising initial results.
Innovation Solution
Administering a low dose of degarelix GnRH antagonist every 28 days, either 240 mg initially followed by 80 mg monthly, or varying doses within a specified range, to suppress testosterone levels effectively while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GnRH agonist therapy is administered to treat prostate cancer, then testosterone levels are suppressed, but testosterone spikes occur causing worsening of patient condition
Solution Approach 1:
The patent inverts the conventional GnRH agonist approach by using a GnRH antagonist (degarelix) that blocks the GnRH receptor instead of activating it. This prevents the initial testosterone surge that occurs with agonists, while still achieving the desired testosterone suppression for prostate cancer treatment.
Solution Approach 2:
The patent changes the pharmacological parameter from agonist activation to antagonist blockade, fundamentally altering how testosterone suppression is achieved. This parameter change eliminates the harmful testosterone spike while maintaining therapeutic effectiveness.
2Reliability
If GnRH antagonist therapy is administered to suppress testosterone, then testosterone levels are reduced, but undesirable side effects like cardiac disorders and urinary tract infections occur
Solution Approach 1:
The patent optimizes the dosing parameter by using a low monthly dose (80mg) administered every 28 days, rather than higher frequencies or doses. This parameter optimization achieves effective testosterone suppression while minimizing the occurrence of side effects like cardiac disorders and urinary tract infections.
Solution Approach 2:
The patent employs periodic monthly administration every 28 days, creating a dosing schedule that maintains therapeutic testosterone suppression while allowing sufficient intervals to minimize cumulative side effects. This periodic action balances efficacy with tolerability.
3Speed
If high dose GnRH antagonist is administered, then testosterone suppression is achieved rapidly, but side effects increase in frequency and severity
Solution Approach 1:
The patent changes the dose parameter from high to low (80mg monthly), demonstrating that rapid testosterone suppression can be achieved without high doses when using the optimized antagonist formulation and dosing interval. This parameter change reduces side effect frequency while maintaining suppression speed.
Solution Approach 2:
The monthly dosing regimen allows the drug to maintain therapeutic levels throughout the month, providing self-sustaining testosterone suppression without requiring frequent high-dose administrations that would increase side effects.
Data Source
AI summary
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.